Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AGIO
stocks logo

AGIO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
12.04M
+12.2%
-1.948
+11.96%
16.04M
+83.86%
-1.930
+24.52%
19.26M
+54.61%
-1.948
+0.91%
Estimates Revision
The market is revising Upward the revenue expectations for Agios Pharmaceuticals, Inc. (AGIO) for FY2025, with the revenue forecasts being adjusted by 3.37% over the past three months. During the same period, the stock price has changed by -23.85%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.37%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-5.02%
In Past 3 Month
Stock Price
Go Down
down Image
-23.85%
In Past 3 Month
Wall Street analysts forecast AGIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGIO is 31.17 USD with a low forecast of 20.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast AGIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGIO is 31.17 USD with a low forecast of 20.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 27.420
sliders
Low
20.00
Averages
31.17
High
48.00
Current: 27.420
sliders
Low
20.00
Averages
31.17
High
48.00
Citi
NULL -> Buy
initiated
$38
2025-11-26
Reason
Citi
Price Target
$38
2025-11-26
initiated
NULL -> Buy
Reason
Citi yesterday morning initiated coverage of Agios Pharmaceuticals with a Buy rating and $38 price target. Citi also opened a "positive 30-Day catalyst watch" on Agios into the December 7 FDA action date for Pyrukynd in thalassemia. It believes the Phase 3 data support approval and thinks the recent selloff in the shares on the sickle cell disease data is overdone.
Truist
Buy
initiated
$32
2025-11-24
Reason
Truist
Price Target
$32
2025-11-24
initiated
Buy
Reason
Truist initiated coverage of Agios Pharmaceuticals with a Buy rating and $32 price target. The company's Pyrukynd franchise is building towards blockbuster status - currently approved opportunity in pyruvate kinase deficiency, PKD, has the potential to expand into thalassemia as early as December of this year, and even sickle cell disease, SCD, next year, with AGIO leveraging strong data across indications for label expansion opportunity, the analyst tells investors in a research note. Truist adds that it expects meaningful value creation from a broad thalassemia label and a key topline SCD readout by year-end, further noting that with positive outcomes in PKD and thalassemia, it is positive on the stock's reward/risk toward its $1.9B peak revenue estimate in 2034.
Leerink
Andrew Berens
Market Perform
to
Outperform
upgrade
$34
2025-11-20
Reason
Leerink
Andrew Berens
Price Target
$34
2025-11-20
upgrade
Market Perform
to
Outperform
Reason
Leerink analyst Andrew Berens upgraded Agios Pharmaceuticals to Outperform from Market Perform with a $34 price target.
Leerink
Market Perform -> Outperform
upgrade
$40 -> $34
2025-11-20
Reason
Leerink
Price Target
$40 -> $34
2025-11-20
upgrade
Market Perform -> Outperform
Reason
As previously reported, Leerink upgraded Agios Pharmaceuticals to Outperform from Market Perform with a price target of $34, down from $40, after the company reported mixed topline results for the Phase 3 RISE UP trial evaluating mitapivat in sickle-cell disease and the stock was down about 51%. With shares approaching cash at about $22 per share, the firm sees no value attributed to mitapivat in approved indication pyruvate kinase deficiency, whicih it values at about $6 per share in its model, or optionality on SCD or MDS. The firm sees the thalassemia PDUFA date on December 7 as a near-term catalyst not reflected at current levels that could confirm the value of the opportunity, the analyst tells investors.
Goldman Sachs
Neutral
downgrade
$40 -> $25
2025-11-20
Reason
Goldman Sachs
Price Target
$40 -> $25
2025-11-20
downgrade
Neutral
Reason
Goldman Sachs lowered the firm's price target on Agios Pharmaceuticals to $25 from $40 and keeps a Neutral rating on the shares. Shares fell sharply after Phase 3 RISE UP results showed strong hemoglobin responses but missed on sickle cell pain crises and fatigue, two endpoints viewed as essential for broader uptake, the analyst tells investors in a research note. The mixed data raises regulatory and commercial uncertainty ahead of the thalassemia PDUFA and potential REMS implications, with attention now shifting to launch expectations and the company's longer-term pipeline and strategy, Goldman says.
JPMorgan
Neutral
downgrade
$37 -> $20
2025-11-20
Reason
JPMorgan
Price Target
$37 -> $20
2025-11-20
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Agios Pharmaceuticals to $20 from $37 and keeps a Neutral rating on the shares. The firm updated its model and lowered its price target following top-line results from the phase 3 RISE UP trial for Pyrukynd in sickle cell disease. The firm also made adjustments to its longer-term expense assumptions and its revenue builds for mitapivat in pyruvate kinase deficiency and mitapivat in thalassemia.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Agios Pharmaceuticals Inc (AGIO.O) is -3.55, compared to its 5-year average forward P/E of -1.86. For a more detailed relative valuation and DCF analysis to assess Agios Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.86
Current PE
-3.55
Overvalued PE
6.10
Undervalued PE
-9.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.49
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.26
Undervalued EV/EBITDA
-4.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
375.62
Current PS
0.00
Overvalued PS
1668.17
Undervalued PS
-916.93
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 297.63% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

AGIO News & Events

Events Timeline

(ET)
2025-11-19
12:00:27
Agios Pharmaceuticals Plummets by 50.1%
select
2025-11-19
11:26:11
Fulcrum's pociredir demonstrates encouraging initial effectiveness compared to mitapivat, according to Leerink.
select
2025-11-19
07:03:28
Agios announces that RISE UP Phase 3 trial of mitapivat achieved its primary endpoint.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-04Globenewswire
Sickle Cell Disease Market Expected to Grow 22.1% by 2034 Driven by New Therapies
  • Market Growth Potential: The sickle cell disease market is projected to grow at a CAGR of 22.1% from 2025 to 2034, primarily driven by advancements in new therapies and disease mechanisms, thereby presenting significant opportunities for pharmaceutical companies.
  • Market Size: In 2024, the sickle cell disease market size reached $650 million, with the United States accounting for approximately 87% of the total market share, indicating the dominant position of the U.S. while also reflecting growth potential in other markets.
  • Emerging Therapies Launch: New therapies such as Pfizer's inclacumab and Novo Nordisk's etavopivat are under development and are expected to significantly alter the market landscape, providing patients with more effective treatment options and enhancing overall treatment outcomes.
  • Rising Patient Demand: The number of sickle cell disease cases is anticipated to rise to 178,500 by 2034, predominantly among individuals aged 18 to 44, which will drive demand for new therapies and further stimulate market growth.
[object Object]
Preview
9.0
11-27NASDAQ.COM
Biotech Stocks Await FDA Verdict in December 2025

  • National Influenza Vaccination Week: Observed from December 1-5, this campaign encourages vaccination against the flu, emphasizing its safety and effectiveness, and serves as a reminder that it's never too late to get vaccinated.

  • World AIDS Day: Celebrated on December 1, this global observance raises awareness about HIV/AIDS, honors those lost, and supports those living with the virus, with a focus on political leadership and human rights to end AIDS as a public health threat by 2030.

  • HIV Statistics: In 2024, approximately 40.8 million people were living with HIV, with around 630,000 deaths from HIV-related causes and 1.3 million new infections, highlighting the ongoing impact of the epidemic.

  • Funding Concerns: There are worries about significant cuts to international HIV funding, particularly from the U.S., which has historically contributed nearly 75% of global financing, with recent reductions affecting key commitments and activities related to World AIDS Day.

[object Object]
Preview
4.0
11-27Benzinga
Citigroup Begins Coverage of Agios Pharmaceuticals with a Buy Rating and Sets Price Target at $38

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Agios Pharmaceuticals Inc (AGIO) stock price today?

The current price of AGIO is 27.42 USD — it has decreased -0.25 % in the last trading day.

arrow icon

What is Agios Pharmaceuticals Inc (AGIO)'s business?

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.

arrow icon

What is the price predicton of AGIO Stock?

Wall Street analysts forecast AGIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGIO is 31.17 USD with a low forecast of 20.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Agios Pharmaceuticals Inc (AGIO)'s revenue for the last quarter?

Agios Pharmaceuticals Inc revenue for the last quarter amounts to 12.88M USD, increased 43.69 % YoY.

arrow icon

What is Agios Pharmaceuticals Inc (AGIO)'s earnings per share (EPS) for the last quarter?

Agios Pharmaceuticals Inc. EPS for the last quarter amounts to -1.78 USD, decreased -110.97 % YoY.

arrow icon

What changes have occurred in the market's expectations for Agios Pharmaceuticals Inc (AGIO)'s fundamentals?

The market is revising Upward the revenue expectations for Agios Pharmaceuticals, Inc. (AGIO) for FY2025, with the revenue forecasts being adjusted by 3.37% over the past three months. During the same period, the stock price has changed by -23.85%.
arrow icon

How many employees does Agios Pharmaceuticals Inc (AGIO). have?

Agios Pharmaceuticals Inc (AGIO) has 486 emplpoyees as of December 05 2025.

arrow icon

What is Agios Pharmaceuticals Inc (AGIO) market cap?

Today AGIO has the market capitalization of 1.60B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free